Exploring the therapeutic landscape of pulmonary hypertension associated with interstitial lung disease, with a focus on idiopathic pulmonary fibrosis: a narrative review
Frontiers in Pharmacology · 23.07.2026 · 17
DOI: 10.3389/fphar.2026.1865787 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 23.07.2026. Verfasst von Nicolò Reccardini und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical, Surgical and Health Sciences, University of Trieste, Trieste, Italy. Die Arbeit nennt 104 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Pulmonary hypertension associated with idiopathic pulmonary fibrosis (PH-IPF) is a frequent and clinically relevant complication that worsens exercise capacity, quality of life, and survival. This narrative review summarizes the epidemiology, pathophysiology, diagnostic approach, and therapeutic landscape of PH-IPF. The development of PH in IPF reflects the combined effects of fibrotic parenchymal destruction, pulmonary vascular remodeling, hypoxic vasoconstriction, endothelial dysfunction, and altered vascular signaling. Diagnosis remains challenging because symptoms often overlap with those of advanced fibrotic lung disease and non-invasive tools have limited sensitivity; right heart catheterization remains the diagnostic gold standard. Antifibrotic agents are central to IPF management but have no established role as PH-targeted therapies. Most pulmonary arterial hypertension therapies have failed to show benefit in PH-IPF or have raised safety concerns, with ambrisentan and riociguat associated with harm. Inhaled treprostinil is currently the only approved therapy with randomized evidence of efficacy in PH associated with interstitial lung disease, including IPF. Supportive care, optimization of comorbidities, referral to expert centers, and timely lung transplantation evaluation remain essential components of management.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical, Surgical and Health Sciences, University of Trieste, Trieste, Italy.
- Department of Pulmonary Rehabilitation, Azienda Sanitaria Universitaria Friuli Centrale, Udine, Italy.
- Department of Pulmonology, Santa Maria Degli Angeli Hospital, Pordenone, Italy.
- Department of Pulmonology, Spedali Civili, Brescia, Italy.
- Department of Pulmonology, University Hospital of Cattinara, Trieste, Italy.
- Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Science, School of Biological Sciences, Faculty of Biological Medicine and Health, The University of Manchester, Manchester Academic He…
Zitieren
APA
Reccardini, N., Da Re, B., Mondini, L., Salton, F., Confalonieri, M., Confalonieri, P., Hughes, M., Monteleone, G., & Ruaro, B. (2026). Exploring the therapeutic landscape of pulmonary hypertension associated with interstitial lung disease, with a focus on idiopathic pulmonary fibrosis: a narrative review. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1865787
Vancouver
Reccardini N, Da Re B, Mondini L, Salton F, Confalonieri M, Confalonieri P, et al. Exploring the therapeutic landscape of pulmonary hypertension associated with interstitial lung disease, with a focus on idiopathic pulmonary fibrosis: a narrative review. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1865787
BibTeX
@article{Reccardini2026,
author = {Reccardini, Nicolò and Da Re, Beatrice and Mondini, Lucrezia and Salton, Francesco and Confalonieri, Marco and Confalonieri, Paola and Hughes, Michael and Monteleone, Giorgio and Ruaro, Barbara},
title = {Exploring the therapeutic landscape of pulmonary hypertension associated with interstitial lung disease, with a focus on idiopathic pulmonary fibrosis: a narrative review},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {17},
doi = {10.3389/fphar.2026.1865787}
}
EUVIMED